SERPINB2 Antibody

What is the molecular structure and cellular localization of SERPINB2 protein?

SERPINB2 (Serpin peptidase inhibitor, clade B, member 2), also known as Plasminogen Activator Inhibitor-2 (PAI-2), is a 415 amino acid serine protease inhibitor with a calculated molecular weight of 47 kDa . It typically appears at 45-47 kDa in Western blot analyses . Unlike many serpins, SERPINB2 lacks a classical secretory signal peptide and primarily exhibits cytoplasmic or nucleocytoplasmic distribution .

SERPINB2 is a member of the ov-serpin subgroup (Clade B serpins) which includes proteinase inhibitors 6, 8, and 9, MENT, Bomapin, and maspin . Confocal microscopy studies have confirmed SERPINB2's predominantly cytoplasmic localization, with some studies showing co-localization with F-actin in focal adhesions and lamellipodia .

How does SERPINB2 expression vary across tissues and cell types?

SERPINB2 demonstrates tissue-specific expression patterns with notable expression in:

• Skin, placenta, and esophagus (highest constitutive expression)

• Blood and vasculature

• Activated monocytes/macrophages (can represent up to 1% of total protein)

Importantly, SERPINB2 expression is dramatically upregulated:

• During pregnancy

• In response to inflammatory stimuli

• In monocytes from HIV-1 infected patients

• In macrophages responding to viral, bacterial and parasitic agents

Cell-specific expression patterns also exist. For example, constitutive expression occurs in Gata6+ large peritoneal macrophages (LPM) , while bone marrow-derived macrophages express SERPINB2 mRNA but minimal protein , indicating significant post-transcriptional regulation.

What are the optimal conditions for detecting SERPINB2 using Western blotting?

Based on validated protocols, the following conditions are recommended for SERPINB2 Western blotting:

For optimal results, employ a dual validation strategy with both a positive control (PMA-induced samples) and negative control (SERPINB2 knockout cells if available) . Note that PMA treatment can dramatically increase SERPINB2 expression in many cell lines, making it an excellent positive control strategy.

What methodologies can validate SERPINB2 antibody specificity before experimental use?

Validating antibody specificity is critical for reliable research outcomes. The following validation strategies have been successfully implemented for SERPINB2 antibodies:

• Genetic knockout validation: Western blot comparing parental and SERPINB2 knockout cell lines (e.g., K562) confirms specificity when bands appear only in parental lines

• Induction testing: Compare untreated vs. PMA-treated samples, as PMA significantly increases SERPINB2 expression

• Multi-application concordance: Test antibody across multiple applications (WB, IHC, ELISA) to verify consistent detection patterns

• Cross-reactivity assessment: For antibodies claiming cross-species reactivity, test on samples from multiple species and confirm appropriate molecular weight bands

• Immunoprecipitation validation: Perform IP followed by Western blot to verify specificity, with recommended conditions of 0.5-4.0 μg antibody per 1.0-3.0 mg total protein lysate

Research has shown that polyclonal antibodies against specific regions (e.g., internal regions) or CD interhelical loop regions demonstrate excellent specificity for SERPINB2.

What experimental approaches can distinguish between SERPINB2's protease inhibition activity and its other functions?

SERPINB2 exhibits both protease inhibition-dependent and independent functions. To differentiate these experimentally:

• Active site mutant models: Utilize SERPINB2 R380A active site mutant mouse models (generated via CRISPR technology) . This mutation specifically disrupts protease inhibition activity while preserving other functions. Comparing wild-type SERPINB2 with R380A mutants allows attribution of effects to either protease inhibition or alternative mechanisms.

• Direct protease activity measurement: Measure uPA proteolytic activity in experimental systems. Studies have demonstrated that increased local invasion in tumors formed with SerpinB2−/− MEFs correlates with significantly elevated uPA activity (654.9±136.0 IU/mg vs. 250.4±51.1 IU/mg in wild-type, p<0.05) .

• Dual intervention approach: Combine SERPINB2 manipulation with specific uPA inhibitors to determine if phenotypes are attributable to uPA inhibition or alternative pathways.

• Protein-protein interaction studies: Investigate interactions between SERPINB2 and non-protease proteins through co-immunoprecipitation and proximity labeling techniques to identify protease-independent functions.

What mechanisms control SERPINB2 transcriptional regulation during inflammation?

SERPINB2 transcription is tightly regulated through several mechanisms:

• Inflammatory induction: LPS can induce SERPINB2 expression via TLR4 by approximately 1000-fold over 24 hours in murine macrophages .

• Critical regulatory elements: Mutation analyses revealed that several elements in the murine SerpinB2 proximal promoter are essential for optimal LPS-inducibility :

  • CCAAT enhancer binding (C/EBP) element

  • Cyclic AMP response element (CRE)

  • Two activator protein 1 (AP-1) response elements

• C/EBP-β dependency: Electrophoretic mobility shift and chromatin immunoprecipitation assays demonstrate that LPS induces the formation of C/EBP-β containing complexes with the SerpinB2 promoter . Both constitutive and LPS-induced SerpinB2 expression were severely abrogated in C/EBP-β-null mouse embryonic fibroblasts and primary C/EBP-β-deficient peritoneal macrophages .

• Enhancer RNA regulation: SERPINB2 expression is regulated by enhancer RNAs with two identified enhancers: Enhancer 1 (containing eRNAs 772, 774, 775) and Enhancer 2 (8kb upstream of the promoter) . Stimulation leads to recruitment of pause-releasing kinase P-TEFb and departure of pause-inducing protein NELF, with RNA immunoprecipitation showing NELF and CDK9 binding to enhancer RNAs after stimulation with distinct kinetics .

How does SERPINB2 modulate immune responses in experimental models?

SERPINB2 functions as a key immune response modulator:

• Th1 response regulation: In SerpinB2−/− mice immunized with OVA in CFA, researchers observed :

  • ~6-fold increase in IgG2c production

  • ~2.5-fold increase in OVA-specific IFN-γ–secreting T cells compared to SerpinB2+/+ littermate controls

• Macrophage-mediated effects: SerpinB2−/− macrophages demonstrated enhanced pro-inflammatory activity :

  • Greater promotion of IFN-γ secretion from wild-type T cells both in vivo and in vitro

  • Increased secretion of Th1-promoting cytokines when stimulated with anti-CD40/IFN-γ or cultured with wild-type T cells

• Migration impact: SerpinB2 negatively regulates macrophage migration, as demonstrated by faster migration of SerpinB2−/− and SerpinB2 R380A macrophages on Matrigel compared to wild-type controls .

• Gene signature effects: Gene set enrichment analyses (GSEA) suggest that SerpinB2 expression (likely via modulation of uPA-receptor/integrin signaling) promotes the adoption of a resolution phase signature in macrophages .

What evidence supports SERPINB2's role in tumor progression and metastasis?

SERPINB2 demonstrates significant impact on tumor behavior:

• Metastasis inhibition: SERPINB2 expression, particularly in the stromal compartment, is associated with reduced metastasis and prolonged survival in pancreatic ductal adenocarcinoma .

• Invasion control: Histological analysis of tumor models showed :

  • Tumors with wild-type MEFs expressing SERPINB2: Well-encapsulated with defined margins and minimal invasion into surrounding muscle or fat

  • Tumors with SerpinB2−/− MEFs: Poorly defined margins with evident invasion into surrounding muscle and fat

• Protease activity regulation: Increased local invasion of tumors formed with SerpinB2−/− MEFs correlated with significantly elevated uPA proteolytic activity (250.4±51.1 IU/mg versus 654.9±136.0 IU/mg in wild-type and SerpinB2−/−, respectively; P<0.05) .

• Neurodevelopmental role: SerpinB2/PAI-2 colocalizes with CHL1 and Vitronectin and mediates neurite outgrowth during post-natal brain development .

• Prognostic implications: Inhibition of uPA by SerpinB2 in tumors is associated with favorable prognosis in multiple cancer types .

How can researchers effectively assess SERPINB2's contribution to tumor microenvironment interactions?

To investigate SERPINB2's role in tumor-stroma interactions:

• Co-culture systems: Develop co-culture models of tumor cells with wild-type vs. SerpinB2−/− stromal cells (particularly fibroblasts) to assess differences in:

  • Invasion capacity

  • Matrix remodeling

  • Cytokine/chemokine profiles

• In vivo xenograft models: Utilize combinations of:

  • Wild-type or SerpinB2-overexpressing tumor cells

  • Wild-type vs. SerpinB2−/− MEFs as stromal components

  • SerpinB2+/+ vs. SerpinB2−/− host animals

• Functional protease assays: Measure uPA proteolytic activity in tumor homogenates using established protocols that have successfully demonstrated significant differences between wild-type and SerpinB2−/− conditions (250.4±51.1 vs. 654.9±136.0 IU/mg) .

• ECM remodeling assessment: Analyze collagen organization and matrix metalloproteinase activity as SERPINB2 has been shown to influence stromal collagen remodeling .

• RNA-Seq analysis: Perform transcriptomic profiling of migrating cells to identify genes associated with migration and extracellular matrix interactions, as this approach has previously revealed that SERPINB2 counter-regulates many Gata6-regulated genes associated with migration .

How should researchers address discrepancies between SERPINB2 mRNA and protein expression data?

SERPINB2 demonstrates significant post-transcriptional regulation, as evidenced by bone marrow-derived macrophages expressing SERPINB2 mRNA but minimal protein . To address such discrepancies:

• Employ multi-level analysis: Always measure both mRNA (by RT-qPCR or RNA-seq) and protein (by Western blot or immunostaining) when studying SERPINB2.

• Include appropriate controls: Use cell types known to express both SERPINB2 mRNA and protein (e.g., PMA-stimulated U937 cells) as positive controls.

• Consider stimulation effects: Different stimuli might differentially affect mRNA vs. protein levels. For example, LPS dramatically increases both, while other conditions might increase only mRNA.

• Examine protein stability: Assess proteasomal degradation by treating cells with proteasome inhibitors to determine if low protein levels despite high mRNA result from rapid degradation.

• Investigate translational regulation: Analyze polysome profiles or perform ribosome profiling to identify translational control mechanisms.

• Assess subcellular localization: SERPINB2 may localize to specific compartments or be secreted under certain conditions, potentially affecting detection by certain methods.

What experimental design considerations are critical when studying SERPINB2 in inflammatory disease models?

When designing inflammation studies involving SERPINB2:

• Selection of appropriate animal models: Consider that SERPINB2 polymorphisms or dysregulated expression are associated with multiple inflammatory conditions :

  • Pre-eclampsia

  • Lupus

  • Asthma

  • Scleroderma

  • Periodontitis

• Cell-specific expression analysis: Different cell types show distinct SERPINB2 expression patterns. Include analysis of:

  • Macrophages (high inducible expression)

  • Dendritic cells (conventional DCs show low levels)

  • Lymphocytes (plasmacytoid DCs, B, T, or NK cells typically show no expression)

• Time-course considerations: SERPINB2 expression is highly dynamic during inflammatory responses, with up to 1000-fold induction over 24 hours in response to LPS . Design experiments with appropriate time points.

• Genetic model selection: Consider both:

  • SerpinB2−/− (complete knockout)

  • SerpinB2 R380A (active site mutant)
    to distinguish between protease inhibition-dependent and independent functions.

• Microenvironmental factors: Consider that SERPINB2 expression can be dramatically affected by the microenvironment, including inflammatory mediators, hypoxia, and cell-cell interactions.